Biogen Inc (NASDAQ:BIIB)
| 304.01 BATS BZX Real-Time Price As of 11:43am ET |  -1.01 / -0.33%Today’s Change | 187.16 Today|||52-Week Range 311.88 | +26.71% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $43.9B |
Company Description
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Contact Information
Biogen, Inc. 225 Binney Street Cambridge Massachusetts 02142 |
Employees
Shareholders
| Mutual fund holders | 55.91% |
| Other institutional | 32.45% |
| Individual stakeholders | 2.53% |
Top Executives
| Christopher A. Viehbacher | President, Chief Executive Officer & Director |
| Alphonse Galdes | EVP-Pharmaceutical Operations & Technology |
| Michael R. McDonnell | Chief Financial Officer & Executive Vice President |
| Mahalakshmi Radhakrishnan | Chief Medical Officer & Group Senior VP |
| Priya Singhal | Head-Research & Development |
